As of August 28, 2020, there were 62,678,613 Common Shares issued and outstanding
Cash runway to fund operations through 2023 / Based on Management’s current expectations and planned development activities
Warrants as at August 5, 2020
|
| Warrants |
|
| Exercise Price |
|
|
|
|
| # |
|
| $ |
|
| Expiry date | December 2015 registered direct offering |
|
| 2,331,000 |
|
|
| 7.10 |
|
| December 13, 2020 | September 2019 registered direct offering |
|
| 3,325,000 |
|
|
| 1.65 |
|
| September 24, 2024 | February 2020 Financing |
|
| 2,608,696 |
|
|
| 1.20 |
|
| August 21, 2025 | February 2020 Financing |
|
| 243,478 |
|
|
| 1.61719 |
|
| February 19, 2025 | July 2020 Financing |
|
| 26,666,666 |
|
|
| 0.45 |
|
| July 7, 2025 | July 2020 Financing |
|
| 1,866,667 |
|
|
| 0.5625 |
|
| July 1, 2025 | August 2020 Financing |
|
| 9,320,907 |
|
|
| 0.47 |
|
| February 5, 2026 | August 2020 Financing |
|
| 869,952 |
|
|
| 0.7040625 |
|
| August 3, 2025 |
|
|
| 47,232,366 |
|
|
|
|
|
|
|
Termine 2020: Q1 ---- Ende PIP 01 (Kindrstudie) 10. März --- Ende der Serie A Warrants 24. März ----- Die 1,65$ September 2019 Warrants dürfen ausgeübt werden 1 April -------Beneficial Ownership Determination Date/ Record Date for Voting 6.April ------- Finale Ergebnisse PIP 01 (positive Results In Dose-finding) 1. Mai ------- Ende der 945T 4,7$ Warrants 15. Mai ------- Annual Meeting 8 Juni -------- Registrierung der 2019 und 2020 Warrants (Verkauf über den Markt zulässig) 25 Juni -------- Megapharm Distribution Agreement 7 Juli ----------- CLOSING OF $12 MILLION PUBLIC OFFERING
5.August -------- CLOSING OF $7 MILLION PUBLIC OFFERING
28.August ---------- Zulassung Novo Somapacitan adult US
13. Dez ---------- Ende der 2,33 Mio 7,1$ Warrants
ca. Jan 2021--------- mögliche Zulassung Novo adult EU
25. Jan 2021 ----------- NASDAQ 1$ Regel (Ende erste 180 Tage)
Q1. 2021 -------- geplant Anfang PIP 02
25.6.21 ----------- mögliche Zulassung Ascendis Pharma pediatric US
Ende Juli 2021 ----------- NASDAQ 1$ Regel (Ende zweite 180 Tage) mögliches Delisting
Q3 2021 -------------- mögliche Zulassung Ascendis Pharma pediatric EU
Q3 - Q4 ------------- mögliche Zulassung Opko Pfizer pediatric US / EU
Q2 2022------- geplant Ende PIP 02
min H1 2023 ------------- AEterna mögliche EMA/FDA Zulassung pediatric US / EU
Zulassungen
28.8.2019 Novo submission BLA adult FDA
ca August 2019 Novo sumbission MAA für EU
26.6 2020 Ascendis Pharma submission BLA pediatric FDA
28.8.2020 Novo Zulassung adult US
8.9 2020 Ascendis Pharma submission MAA pediatric EMA
bald Opko/Pfizer submission BLA pediatic https://www.fiercebiotech.com/biotech/...ormone-data-ahead-fda-filing
ca. 1.2020 mögliche Zulassung Novo adult EU
25.6.2021 PDUFA Ascendis Pharma pediatric US
ca Q3 2021 mögliche Zulassung Ascendis Pharma pediatric EU
|